Anti-lymphocyte, anti-monocyte, and anti-endothelial cell antibodies in chronic haemodialysis patients


DİRESKENELİ R. H., Özgön S., Özener C., Lawrence R., Erman M., Sarsmaz N., ...Daha Fazla

Nephrology Dialysis Transplantation, cilt.7, sa.5, ss.422-426, 1992 (SCI-Expanded) identifier identifier identifier

Özet

Patients receiving chronic haemodialysis treatment are known to have a high prevalence of anti-panel antibodies (anti-lymphocyte, antimonocyte, and anti-endothelial cell) originating from a number of different possible sensitizing events such as blood transfusions, multiparity, or renal transplantation. © 1992 European Dialysis and Transplant Association-European Renal Association.